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Abstract  
 
Aims - In heart failure non-adherence increases events, in turn, the effect of 
hospitalization on adherence is incompletely understood. We explored the relationship of 
non-adherence with outcomes, hospitalizations with non-adherence and the influence of 
non-adherence on treatment effects of heart rate lowering with ivabradine.  
 
Methods and results - In the randomized, controlled Systolic Heart failure treatment 
with the If-inhibitor ivabradine Trial (SHIFT), we studied the effect of non-adherence 
(N=1287) compared to adherent patients (N=5204) on cardiovascular outcomes. After 
adjustment, non-adherence was associated with the primary composite endpoint of 
cardiovascular death and heart failure hospitalization (hazard ratio 3.47, 2.91-4.13, 
p<0.0001). No interaction with the treatment groups of placebo or ivabradine (p for 
interaction 0.54) occured. Similar results for cardiovascular death, heart failure 
hospitalization as well as for cardiovascular hospitalization, heart failure death and total 
death were observed. The effect of ivabradine was maintained in patients being 
adherent or becoming non-adherent during the trial (p for interaction = 0.54). Patients 
with a previous hospitalization were more likely to become non-adherent thereafter. 
 
Conclusions – Non-adherence identifies a group at particularly high cardiovascular 
event risk independent of treatment allocation. Non-adherent patients in the ivabradine 
group maintain a treatment benefit. Patients with previous hospitalizations are more 
likely to become non-adherent and represent a group of particular high risk patients in 
whom special attention to stimulate adherence may be valuable. 
 
Clin Trial Registration – URL: http:/www.clinicaltrials.gov. Unique identifier 
ISRCTN70429960.  
Key words: heart failure – SHIFT – heart rate – adherence – cardiovascular 
hospitalizations 
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Introduction 
Chronic heart failure is highly prevalent in the United States (1) and Europe (2). Its 
prevalence is associated with age and increases to >10% at the age of 80 years and 
older (3). Evidence has shown that certain treatments reduce morbidity and mortality 
(2). However, adherence to these medical therapies has been limited, apparently 
occurring in 40-60% of patients with heart failure (4) and other chronic diseases, in 
which long-term therapies are indicated (5). Non-adherence to medication is related 
to poor outcomes in various conditions like heart failure (4), in high risk settings after 
vascular events (6), hypertension (7,8), after myocardial infarction (9) and in patients 
on oral anticoagulation (10). Non-adherence is also a common precipitant for heart 
failure readmissions (11). In clinical trials, non-adherence to study medications with 
statins (12), beta blockers (13), anti-hypertensive agents (7,8,14) and inhibitors of the 
renin-angiotensin system (6) are associated with cardiovascular complications, the 
effect being similar to investigations outside clinical trials (5,11). Non-adherence to 
medical interventions in general, including placebo applications, has impacted 
outcomes (15,16). This effect, referred to as the “healthy adherer phenomenon” is 
associated with adverse health care behaviors and related to the fact of being non-
adherent to any medical advice or intervention (15,16). In this analysis of the Systolic 
Heart failure treatment with the If-inhibitor Trial (SHIFT), we investigated the effects 
of adherence in patients on the study medications ivabradine or placebo. SHIFT 
investigated the effect of heart rate reduction in 6505 patients with systolic heart 
failure and a heart rate of > 70 bpm in sinus rhythm and receiving evidence-based 
contemporary medical treatments (17). We looked at outcomes on placebo and 
ivabradine in adherent and non-adherent patients and also investigated whether, 
after a nonfatal hospitalization, the rate of non-adherence is changed. 
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Methods  
Study design and study population  
SHIFT was a randomized, double-blind, placebo controlled outcomes trial in patients 
with sinus rhythm and chronic moderate to severe heart failure. Patients were 
included with a resting heart rate > 70 bpm in sinus rhythm and an ejection fraction < 
35%. In 37 countries (677 medical centers), a total of 6505 patients were randomized 
to either placebo or ivabradine with a starting dose of 5 mg bid, which could be up-
titrated to 7.5 mg bid or reduced to 2.5 mg bid after a titration interval of 28 days; up- 
or down-titration dependent on achieved heart rate and tolerability of the study drug. 
Heart rate was measured on two consecutive visits prior to randomization by a 12-
lead electrocardiogram, which was repeated at baseline and at every follow-up visits 
during the study period. The design (17) and the primary results (18) have been 
reported previously. All outcomes were confirmed by an Adjudication Committee 
according to described criteria (17). SHIFT showed that heart rate reduction with the 
If-inhibitor ivabradine reduced the composite of cardiovascular death and heart failure 
hospitalization in patients at a heart rate > 70 bpm (18). In patients with a heart rate > 
75 bpm cardiovascular death and all-cause death (19) also were reduced. Lowest 
event rates were achieved when heart rate on drug fell below 60 bpm (20).  
 
Procedures 
Study personnel recorded adherence as the number of blinded study pills taken as a 
proportion of those distributed according to the protocol. This procedure was done at 
each follow-up visit, which took place after inclusion, at day 14, at day 28, at 4 
months and every 4 months thereafter until the final visit (e.g., month 48). Adherence 
was defined as being on the study medication (active drug or placebo) throughout the 
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total period of the study, while non-adherence was defined as premature and 
permanent stopping of either study drug (ivabradine or placebo). Temporary 
interruptions of study drugs were not regarded as being non-adherent, because 
investigators and patients were advised to reintroduce study medications in case of 
temporary interruptions. 
 
Patients 
We explored the baseline characteristics in adherent and non-adherent patients 
according to demography, cardiac parameters, medical history and concomitant 
medications, for all patients and separately by treatment group. Secondly, we looked 
at the time dependence of becoming non-adherent on placebo or ivabradine in each 
of the treatment groups. Finally, the following cardiovascular outcomes were 
tabulated separately in patients adherent or non-adherent to ivabradine or placebo: 
the SHIFT primary composite of cardiovascular death and heart failure 
hospitalization, the individual components of the primary composite, total death, heart 
failure death and cardiovascular hospitalizations. All events in the non-adherent 
group and adherent group were analyzed at each assessment point during the trial or 
after the patients had stopped study medication. It was observed that several 
patients withdrew from study medication because of an event. Therefore, we set out 
to investigate the effect of non-fatal events on the subsequent occurrence of non-
adherence to study drugs. Finally, the treatment effect of ivabradine was assessed as 
a function of adherence or non-adherence to study drug.  
 
Statistical analysis  
Descriptive statistics are presented as median or mean + standard deviation (SD) for 
continuous variables and as numbers and percentages for categorical variables. 
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Patients were divided into those adherent and non-adherent to study medication. 
Statistics in these groups were tested for differences using analysis of variance for 
continuous data and chi2 for categorical data. Variation of events across the groups 
was tested in a Cox proportional hazard model adjusted for beta blocker use, New 
York Heart Association class, left ventricular ejection fraction, ischemic heart failure, 
age, estimated glomerular filtration rate, body mass  index, history of diabetes, and 
baseline heart rate. Hazard ratios were calculated with reference to the lowest test 
groups. SAS (version 9.2) was used for all analyses.  
 
Results  
Patient Characteristics. 
In SHIFT, 6505 patients were randomized to treatment groups (3268 ivabradine, 
3290 placebo). For this analysis, data on adherence were available in 6491 patients. 
5204 patients were adherent, while 1287 patients were non-adherent, i.e., 
persistently stopped study medication before their final visit or death. The number of 
non-adherent patients steadily increased over time. Figure 1 depicts the time to 
withdrawal from study medications for each of the treatment groups. Slightly more 
patients in the ivabradine group withdrew from study medication compared to those 
in the placebo group (21% vs 19%, p = 0.0141). Supplement Table 1 summarizes the 
baseline characteristics by adherence with study medication overall and by treatment 
group. An increased risk of non-adherence with study medications was associated 
with older age, lower body mass index, higher heart rate, lower left ventricular 
ejection fraction, impaired renal function, higher NYHA class, longer duration of  heart 
failure, history of atrial fibrillation, and lower beta blocker use. Formally, statistical 
differences with device therapies were affected by low numbers of patients. Factors 
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associated with non-adherence were similar in patients on ivabradine or placebo 
(supplement table 1).  
 
Effect of non-adherence 
Figure 2 shows the effect of becoming non-adherent in patients treated with 
ivabradine or placebo on the primary endpoint (left), heart failure hospitalization 
(middle) and cardiovascular death (right). For the primary endpoint and its 
components, there was a markedly higher event rate when patients withdrew from 
study medication, ivabradine or placebo, compared to when patients adhered to 
study medication. Nonetheless, the difference between ivabradine and placebo was 
apparent both in patients who became non-adherent and those who adhered to study 
drugs. Surprisingly, the difference between ivabradine and placebo was larger in 
patients who became non-adherent. For cardiovascular death, there was no 
difference in adherent patients, but there was a difference in the non-adherent 
patients in favor of ivabradine compared to placebo (Figure 2, right). Similar results 
were observed for total death (supplement figure 1, left), heart failure death 
(supplement figure 1, middle) and cardiovascular hospitalization (supplement figure 
1, right). For adherent patients, there was no difference in cardiovascular death 
(figure 2), total death and heart failure death (supplement figure 1), whereas there 
was a difference between ivabradine and placebo in non-adherent patients. There 
was a significant increase of hazard for placebo (Figure 3, left) and ivabradine 
(Figure 3, right) in non-adherent compared to adherent patients.  
 
Suppl. Figure 2 depicts the event rates in patients who became non-adherent after a 
cardiovascular event. The differences between adherent and non-adherent patients 
for the primary endpoint (Suppl. Figure 2, left), heart failure hospitalization (Suppl. 
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Figure 2, middle) and cardiovascular death were apparent. Suppl. Figure 3 shows 
similar results for total death (left), heart failure death (middle) and cardiovascular 
hospitalization (right). Again, adherence was not associated with any differences in 
mortality endpoint rates, but a difference between ivabradine and placebo on event 
rates is apparent once patients become non-adherent. Suppl. Figure 4 shows the 
hazard ratio for cardiovascular events occurring after study drug withdrawal. On 
placebo and on ivabradine, the trends for increasing hazard ratios after becoming 
non-adherent were smaller and were not significantly different on placebo and 
ivabradine for heart failure hospitalization and cardiovascular hospitalization. 
However, there was no heterogeneity of the effect of becoming non-adherent after an 
event on placebo or ivabradine (Suppl. Figure 4).  
 
Treatment effect of ivabradine in adherent and non-adherent patients 
Figure 4 summarizes the effect of ivabradine compared to placebo in patients 
becoming non-adherent (left) or remaining adherent (right) on the primary composite 
endpoint (Figure 4A), cardiovascular death (Figure 4B) and heart failure 
hospitalization (Figure 4C). In adherent patients the overall event rate was lower than 
in non-adherent patients regardless of assignment to on placebo or ivabradine. 
Furthermore, the difference between ivabradine and placebo was greater in non-
adherent patients while in adherent patients only the primary endpoint cardiovascular 
death was significantly reduced by ivabradine. Results were similar for total death 
(Supplement Figure 5A), heart failure death (Supplement Figure 5B) and 
cardiovascular hospitalization (Supplement Figure 5C) in non-adherent (left) and 
adherent (right) patients. Treatment effects in non-adherent and adherent patients 
are summarized in Figure 5. In non-adherent patients (left), the treatment effect of 
ivabradine was significant for all endpoints while in adherent patients (right) 
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significance was demonstrated only on cardiovascular death, heart failure death and 
total death. However, there was no significant trend for heterogeneity between the 
treatment effects in the non-adherent and adherent groups.  
 
Effects of hospitalizations on adherence 
To explore the effect of cardiovascular morbidity on adherence, we studied the 
association of heart failure hospitalization and cardiovascular hospitalizations on 
becoming non-adherent thereafter. Among all patients becoming non-adherent 
(N=1287), 26.6% (N=342) became non-adherent after a previous heart failure 
hospitalization, while in the 5204 patients remaining adherent, only 13.6% (N=705) 
had a previous hospitalization (p<0.0001). Similar results were obtained after 
separation by treatment groups: 30.3% of patients on placebo (N=183) who had 
previous heart failure hospitalization then became non-adherent; only 15.9% (N=420) 
of adherent patients had a previous heart failure hospitalization (p<0.0001). Similar 
results were obtained for ivabradine: 23.3% (N=159) non-adherent and 11.2% 
(N=285) adherent patients experienced a heart failure hospitalization (p<0.0001). 
Figure 6A provides Kaplan Meier plots for time to permanent study drug withdrawal 
by previous heart failure hospitalization on placebo (left) and on ivabradine (right). In 
both treatment strata there was a significant effect (log rank < 0.0001) of heart failure 
hospitalization on subsequently becoming non-adherent to placebo or ivabradine. 
Parallel results were obtained for previous cardiovascular hospitalizations (Figure 6B) 
on placebo (left) or on ivabradine (right). We further explored the hazard of becoming 
non-adherent by previous heart failure hospitalizations (Figure 7A) or cardiovascular 
hospitalization (Figure 7B). The results were similar for placebo and for ivabradine 
and similar for cardiovascular hospitalizations (Figure 7B). In the first 30 days after 
becoming non-adherent, HR was 71.6 ± 13.5 bpm (n=291) on ivabradine and 74.2 ± 
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14.0 bpm (n=229) on placebo. In those becoming non-adherent, HR remained 
predictive for heart failure hospitalizations after withdrawal of ivabradine (above 
median 70bpm : 52 (34%), 30 prior and 23 after becoming non-adherent; below 
median: 24 (17.8%), 14 prior, 10 after becoming non-adherent). 
 
Discussion 
The SHIFT database provided the opportunity to study the effect of non-adherence 
on outcomes and of non-fatal outcomes on non-adherence in a population with 
systolic heart failure on contemporary guideline-recommended background 
treatments. The discontinuation of study medication was considered a surrogate for 
non-adherence to medications in general and the adherence to placebo was 
considered a surrogate for adherence per se (rather than the effect of the specifically 
tested drug, ivabradine). We showed that in both groups, randomized to ivabradine or 
placebo, non-adherence had a strong impact on i) the primary outcome and its 
components, heart failure hospitalization and cardiovascular death, as well as ii) the 
secondary outcomes of total death, heart failure death and cardiovascular 
hospitalizations. The impact was smaller when the effect of non-adherence was 
evaluated after the patients became non-adherent. The treatment effect of ivabradine 
was maintained in adherent patients but also in non-adherent patients. Our results 
extend previous observations showing that patients who experienced a non-fatal 
hospitalization had an increased rate of becoming non-adherent (6).  
 
Prediction of risk by non-adherence  
Non-adherence to heart failure medications has been associated with higher mortality 
and increased hospitalizations (4,5,9,11) resulting in increased health care costs 
(21,22). Non-adherence is related to patient characteristics like age (23), cognitive 
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dysfunction and depression (24,25). Since heart failure patients are often elderly with 
a high load of comorbidities requiring polypharmacy (26) and heart failure therapies 
are often complex and costly (27), these patients represent a group at particular high 
risk for non-adherence and subsequently high event rates. This might contribute to 
the finding that, although several treatments are effective, the mortality and 
hospitalization rate remains relatively high (28,29). Herein, we observed 
discontinuation rates of 19% (placebo) to 21% (ivabradine) after approximately 1000 
days. Our findings are comparable to previous heart failure studies except that, in the 
earlier studies, a highly variable non-adherence rate was observed (27). This might 
be due to the fact that under trial conditions more frequent monitoring occurs, which 
potentially results in a higher adherence rate than in general practice, due to more  
patient-physician contacts as well as the prescriber continuity in the context of 
complex treatment regimen (28). As in previous studies (29), it is difficult to 
distinguish between non-adherence and drug discontinuation by adverse events. The 
fact that on ivabradine non-adherence was slightly higher than on placebo may be 
attributable to the relatively smaller portion of patients who discontinued after adverse 
events on ivabradine compared to placebo, although ivabradine was reported to be 
well tolerated (18).  
 
Effect of non-adherence on outcomes  
SHIFT patients becoming non-adherent were more likely to develop primary 
outcomes consisting of cardiovascular death and heart failure hospitalization as well 
as total death, heart failure death and cardiovascular hospitalizations. Based on the 
Cox model analyses, there was a difference between patients being off at any time 
during the follow-up or when events were only counted after patients became non-
adherent to study medication. This provides evidence that non-fatal events triggering 
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non-adherence might have an important impact on outcomes and non-adherence. 
Interestingly, as previously observed in the CHARM trial (16), non-adherence was 
highly prevalent in patients on placebo. This provides evidence that being non-
adherent with study medication is a marker of being non-adherent to health care 
recommendations in general and in particular accompanying heart failure therapies. 
Heart failure medication other than the study drugs were not captured in SHIfT and 
also information on drop-in medications was not recorded. Therefore, it is important 
to know that the non-adherence rate to other drugs such as beta blockers, 
angiotensin-converting-enzyme-inhibitors/angiotensin receptor-blockers and 
aldosterone-antagonists might have contributed to the differences between adherent 
and non-adherent patients on placebo. In support of this notion, non-adherence rates 
to other medications was reported to be relatively high, amounting to 65% for beta 
blockers, 56% for spironolactone and 79% for renin-angiotensin antagonists (30). 
Interestingly, the treatment effect of ivabradine was maintained in non-adherent and 
adherent patients suggesting  that being on a heart rate reducing agent for a short 
time might provide prolonged beneficial effects on outcome, a finding which is in 
agreement with the so called “legacy effect”  observed in long-term studies with ACE-
inhibitors (31) and statins (32).  
 
Effect of events on becoming non-adherent  
Patients who experienced a hospitalization subsequently showed a sharp increase in 
the rate of non-adherence. Therefore, the increased load of morbidity or potentially 
also a loss of trust in medical interventions might have contributed to this 
observation. This finding identifies those patients who have suffered a cardiovascular 
event as a group with particular high risk to become non-adherent and subsequently 
to experience even more complications. Thus, non-adherence leading to events and 
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events leading to non-adherence may be a vicious circle for heart failure patients, 
creating a particularly high risk. Therefore, special attention must be paid to 
individuals suffering from a non-fatal event for special strategies to improve 
medication adherence (33). For example, psychological interventions addressing 
depressive symptoms and pharmacy based interventions have been shown to 
improve medication adherence (33, 34, 35).  
 
Study limitation  
This analysis was performed to identify effects of non-adherence according to study 
drug withdrawal on cardiovascular outcomes. In this analysis as in studies reported 
previously (15,16), a strong “healthy adherer effect” was observed. We cannot draw 
any conclusions on the mechanisms involved in the increased event rates in the 
placebo group. The effect of withdrawing accompanying heart failure therapies as 
well as non-adherence to lifestyle recommendations might have contributed. 
However, these confounders are usually not captured in trial protocols. We defined 
non-adherence as permanent stop of study medication, while it was defined as being 
on drug < 80% of the time in a previous trial (16). However, this approach gets 
imprecise when patients had only few study visits. Furthermore, phenomena like 
“drug holidays” and “tooth brushing” effects are not captured by either approach 
(8,25). Thus, being off study medication is one among other markers of non-
adherence. Secondly, this is a retrospective analysis which was not based on 
randomized comparisons and cannot compare individual drugs, because such an 
analysis would have been confounded by different known and unknown patients’ 
characteristics or potential differences in the care provided to patients outside the 
trial. These were not captured in SHIFT, which aimed to investigate the effect of 
ivabradine on outcomes in individuals with systolic heart failure. Finally, care of these 
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patients outside the trial was provided by treating physicians. There might have been 
a great variety of physician-patient contacts and quality of care in between included 
patients. Many factors potentially predicting non-adherence like frailty, family support, 
personality characteristics among many others cannot be captured in a trial like this.  
Conclusions 
This analysis of the large SHIFT database shows that non-adherence is a strong 
predictor of cardiovascular outcomes in patients with heart failure. One important 
trigger of non-adherence was suffering a non-fatal hospitalization. Patients after a 
non-fatal event are a particular high risk group at danger of becoming non-adherent 
and develop consequently more cardiovascular complications thereafter. This group 
of patients provides a special group at high risk to be targeted by psychological or 
medical strategies including tight follow-ups to improve medical adherence and to 
prevent events. The treatment effect of heart rate lowering with ivabradine is 
maintained in patients who are adherent and who become non-adherent to 
ivabradine, even though they have not been on the drug for the full study period. 
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Legends to figures  
 
Figure 1 
Permanent stop of study medication over time on ivabradine or placebo.  
 
Figure 2  
Kaplan Meier curves for the primary endpoint (left), heart failure (HF)-hospitalization 
(middle) and cardiovascular (CV) death (right) in patients adherent or non-adherent 
to ivabradine or placebo.  
 
Figure 3  
Hazard ratios on non-adherence on outcomes on placebo (left) or ivabradine (right).  
CV: cardiovascular; HF: heart failure 
 
Figure 4  
Kaplan Meier curves for the treatment effect of ivabradine vs placebo on the primary 
endpoint (A, composite of cardiovascular death and heart failure hospitalization), 
heart failure (HF) hospitalization (B), cardiovascular (CV) death (C).  
 
Figure 5  
Hazard ratios of the effect of ivabradine versus placebo in patients becoming non-
adherent or staying adherent during follow-up. 
CV: cardiovascular; HF: heart failure  
 
Figure 6  
Kaplan Meier curves for becoming non-adherent after a previous heart failure 
hospitalization (A) or a previous cardiovascular hospitalization (B) on placebo (left) or 
ivabradine (right). 
 
Figure 7 
Hazard Ratio for becoming non-adherent after a previous heart failure hospitalization 
(A) or a previous cardiovascular hospitalization (B) on placebo (left) or ivabradine 
(right). 
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